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Received December 31, 2010; accepted July 5, 2011AbstractBackground: Metastasectomy is the standard treatment for patients with resectable liver metastasis from colon cancer. This study aimed to
determine the impact of initial stage on overall survival (OS) after metastasectomy.
Methods: A retrospective analysis of 2804 patients diagnosed with colon cancer between 1999 and 2008.
Results: Of the cohort, 38.1% of the patients were stage IVor had recurrence after curative surgery, and 131 received liver metastasectomy. The
5-year survival rate for patients after liver metastasectomy was 42.1%. The 5-year survival rates after metastasectomy for initial stage I disease,
stage II disease, stage III disease, and stage IV disease were 100%, 82.5%, 31.8%, and 36.9%, respectively ( p¼ 0.014). When patients were
grouped as initial stage I/II and stage III/IV, the 5-year survival rate after liver metastasectomy differed significantly (83.9% vs. 35.7%,
p¼ 0.006). Patients with initial stage I/II disease after liver metastasectomy had a significantly better 5-year progression-free period compared to
those with stage III/IV disease (60% vs. 28%, p¼ 0.021), which was due to the lower recurrence rate in the stage I/II group.
Conclusion: Our results suggest that patients who receive liver metastasectomy for metastatic colon cancer should be grouped into two groups:
those with initial stages I and II disease, and those with stages III and IV disease, since the progression-free survivals (PFS) and OS after
metastasectomy in these two groups differ significantly.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: colorectal neoplasms; hepatectomy; neoplasm metastasis1. Introduction
Colon cancer is one of the most common malignancies
worldwide, and nearly half of colon cancer patients have either
metastatic disease at the time of diagnosis or develop metastases* Corresponding author. Dr. Hao-Wei Teng, Division of Hematology-
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doi:10.1016/j.jcma.2011.09.004during the course of their disease. The incidence of colon cancer
presenting as stage IV disease is approximately 19%.1 In one
multicenter study, the reported 5-year recurrence rates for stage I,
II, and III colon cancer were 2.7%, 12.1% and 24.3%, respec-
tively.2 The liver is themost common site ofmetastasis, and if left
unresected, survival time beyond 5 years is close to zero.3
The management of stage IV disease and recurrent colon
cancer with liver metastasis has evolved over the past decade,
reflecting the integration of new imaging technologies,
advanced surgical methods, and new drug regimens. Suchhinese Medical Association. All rights reserved.
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cetuximab. The standard treatment strategy for resectable
metastatic colon cancer is synchronous metastasectomy. For
disease that is potentially convertible to resection, the treat-
ment is metachronous metastasectomy after chemotherapy,
provided that clear surgical margins can be obtained4 and
adequate residual organ function remains.5
Until now, the 5-year survival rate after liver meta-
stasectomy reported in the literature has ranged from 12% to
58%.4,6e11 The wide range of reported 5-year survival rates is
the result of variations in patient selection, criteria of resect-
ability, the use of adjuvant chemotherapy and surgical exper-
tise. However, in recent years, most studies in the literature
have focused on overall survival (OS) or progression-free
survival (PFS) after metastasectomy, regardless of the initial
disease stage at diagnosis. The patients in these studies were
usually analyzed statistically as a single population, because
the number of patients was often limited to a single institute or
surgical case series.
We retrospectively analyzed data from a single institution
to examine the impact of initial disease stage on OS after liver
metastasectomy in patients with colon cancer. The recurrence
pattern after metastasectomy was also examined.
2. Methods
From January 1999 to January 2008, 1783 men and 1021
women were consecutively diagnosed with stage I through IV
colon cancer at the Taipei Veterans General Hospital, Taiwan.
Disease stage was based on the American Joint Committee on
Cancer staging system, sixth edition.12 All patients with a non-
carcinoma tumor histology were excluded. For stage I through
III colon cancers, we included only patients who were treated
with curative surgery. Patients with rectal cancer were
excluded due to the diverse strategies for the application of
concurrent chemotherapy and radiation therapy, in locally
advanced and low-lying tumors. Informed consent was ob-
tained from all patients prior to enrolment.
Clinical-pathological staging and clinical course were
determined by examining a computer database containing
detailed information of all histology-proven colon cancer
patients. Follow-up information and survival data were ob-
tained from hospital records and the National Cancer Registry.
Left colon cancer was defined as malignant in the splenic
flexure, descending colon, sigmoid, and/or rectosigmoid
colon, and right colon cancer was defined as that occurring in
the cecum, ascending colon, hepatic flexure and/or transverse
colon. The decision for metastasectomy was made by physi-
cians after considering the extent of the metastatic lesions and
condition of the individual patient. Extra-liver metastasis was
an absolute contraindication for liver metastasectomy.
Death from any cause was regarded as an event. Patients
who remained alive at the end of the follow-up period were
censored. OS was defined as the time from metastasectomy to
death from any cause. PFS was counted from the date of
metastasectomy to the date of confirmation of recurrence.
Synchronous metastasectomy was defined as resection ofboth metastatic and colonic lesions performed at initial
hospitalization, and metachronous metastasectomy was
defined as resection of metastatic and colonic lesions per-
formed at separate hospitalizations. Surgical mortality was
defined as death within 30 days after liver metastasectomy.
The follow-up period in this study ended in January 2009,
or at the death of the patient. Patients were followed up for the
first 2 years at least every 3 months from time of diagnosis,
then every 6 months for 5 years, and then annually until death.
Follow-up visits included physical examination, rectodigital
examination, carcinoembryonic antigen (CEA) level, chest
X-ray, abdominal sonogram and/or abdominal computed
tomography (CT) scanning. If recurrence was suspected,
further examinations such as chest CT, whole-body bone scan,
or whole-body positron emission tomography (PET) scan were
performed.2.1. Statistical analysisAll statistical analyses were performed using SPSS statistical
software version 16.0 for Windows (SPSS, Inc., Chicago, IL,
USA).13 Survival curves were computed according to the
KaplaneMeier method and compared by the log-rank test.
Formal comparisons across groups were made with the Fisher’s
exact test (categorical variables). All hypothesis tests were two-
sided. Cox regression analyses were performed to assess the
independent prognostic significance of different factors. Avalue
of p< 0.05 was considered statistically significant.
3. Results3.1. Patient characteristics and 5-year OSA total of 2804 patients met the inclusion criteria and were
analyzed. Patient characteristics are presented in Table 1. The
percentages of patients with stages I, II, III, and IV disease
were 12.8%, 30.4%, 26.8%, and 30%, respectively. All stage I
through stage III patients underwent curative surgical resec-
tion with clear histologic margins.
The 5-year survival rate for the entire cohort after diagnosis
was 55.1% (n¼ 2804). The 5-year survival rate by stage was
86.9% for stage I disease, 77.8% for stage II disease, 60.6%
for stage III disease, and 10.5% for stage IV disease (Fig. 1).
For the patients who received liver metastasectomy (n¼ 131),
the 5-year survival rate after metastasectomy was 42.1%
(Fig. 2).3.2. Characteristics and OS of metastasectomy
according to initial stageA total of 131 patients received liver metastasectomy. Of
these, 77 (58.8%) patients received synchronous meta-
stasectomy and 54 (41.2%) received metachronous meta-
stasectomy. The basic characteristics of the patients who
received liver metastasectomy are presented in Table 2. A total
of 74/131 patients (56.4%) developed recurrence during
follow-up.
Table 1
Patient’ characteristics (n¼ 2804).
Gender Number %
Male/female 1783/1021 (63.6/36.4)
Race
Chinese 2804 (100)
Age (y)
Mean 66.5 e
Range 18e102 e
Pathology
Adenocarcinoma 2734 (97.50)
Carcinoma 24 (0.86)
Mucinous adenocarcinoma 36 (1.28)
Mucinous carcinoma 1 (0.04)
Mucinous cystadenocarcinoma 2 (0.07)
Signet ring cell carcinoma 7 (0.25)
Location
Right 1134 (40.40)
Left 1670 (59.60)
AJCC stage
I 359 (12.80)
IIA 767 (27.35)
IIB 86 (3.07)
IIIA 52 (1.85)
IIIB 419 (14.94)
IIIC 280 (9.99)
IV 841 (29.99)
Fig. 2. The overall survival (OS) of all the patients who underwent liver
metastasectomy.
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initial stage I, II, III, and IV disease are presented in Fig. 3A.
The 5-year survival rate was 100%, 82.5%, 31.8%, and 36.9%
in patients with initial stage I, II, III, and IV disease,Fig. 1. The overall survival (OS) ofrespectively, which differed significantly in each stage
( p¼ 0.014). As shown in Fig. 3B, it was much lower for
patients of initial stages III/IV (35.7 % at 5 years) than for
those of stages I/ II (83.9% at 5 years, p¼ 0.006).3.3. PFS after liver metastasectomyAs seen in Fig. 4A, patients with initial stage I/II disease
after liver metastasectomy had a significantly better PFS than
patients with stage III/IV disease ( p¼ 0.021). Moreover, the
30-month relapse rate was significantly higher in patients withall patients according to stage.
Table 2
Characteristics of patients who received liver metastasectomy (n¼ 131).
Gender Number %
Male/female 82/49 (62.6/37.3)
Race
Chinese 131 (100)
Age (y)
Mean 62.0
Range 25e84
Pathology
Adenocarcinoma 128 (97.9)
Carcinoma 1 (0.7)
Mucinous adenocarcinoma 2 (1.4)
Location
Right 57 (43.5)
Left 74 (56.5)
AJCC stage
I 1 (0.8)
IIA 13 (9.9)
IIB 1 (0.8)
IIIA 0 (0)
IIIB 15 (11.5)
IIIC 7 (5.3)
IV 94 (71.7)
CEA ng/mL
Mean 63.1
Range 1.6e2476
Surgical margin
R0 119 (90.8)
R1,R2 12 (9.2)
Relapse pattern (n¼ 74)
Liver 33 (44.6)
Not liver 41 (55.4)
Frequency of metastasectomy
1 123 (93.6)
2 7 (5.6)
3 1 (0.8)
Number of liver metastases at operation
<4 122 (93.1)
4 9 (6.9)
Regimen of adjuvant chemotherapy after metastasectomy
Oxaliplatin-based 33 (25.2)
Irinotecan-based 41 (31.3)
5-FU-based 39 (29.8)
Observation 18 (13.7)
Surgical mortality <30 days 1 (0.7)
CEA¼ carcinoembryonic antigen; FU¼ fluorouracil.
Fig. 3. The overall survival (OS) of the patients with stages I, II, III and IV
disease who received liver metastasectomy: (A) OS after metastasectomy of
stage I to IV; (B) OS after liver metastasectomy dividing patients to stage IeII
and IIIeIV.
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regardless of stage, most patients experienced recurrence
within 30 months (93.2%, p¼ 0.222).3.4. Univariate and multivariate analysis of possible
prognostic factors associated with OS to liver
metastasectomySeveral prognostic factors for liver metastasectomy were
analyzed (Tables 3 and 4). Univariate analysis revealed thatthe primary tumor stage ( p¼ 0.006), the number of metastases
found in the liver when receiving liver metastasectomy
( p¼ 0.003), and the metastatic tumor distribution ( p¼ 0.038)
significantly affected the OS. Other risk factors such as
elevated CEA, diagnosis interval, adjuvant chemotherapy
regimens and receipt of adjuvant chemotherapy, were also
investigated but did not reach statistical significance for OS.
Multivariate analysis showed that primary tumor stage was
an independent factor for predicting OS after liver
metastasectomy.4. Discussion
A total of 2804 patients were diagnosed with colon cancer
from 1999 to 2008 at our hospital. Among them, 30% were
initially diagnosed as stage IV disease. We found that almost
20% of patients who did not have metastatic disease at initial
Fig. 4. (A) Progression-free survival (PFS) after liver metastasectomy: stage I/II versus stage III/IV.; (B) Distribution of recurrence after liver metastasectomy, stage
I/II versus stage III/IV.
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38.1% of patients eventually developed stage IV or recurrent
disease. Among all colon cancer patients, only 131 (12%)
received liver metastasectomy. The 5-year survival rate after
liver metastasectomy was 42.1%, which is similar to previous
reports.4,6e11 The relatively low metastasectomy rate was
attributed to surgeon preference, as most surgeons only per-
formed resection in patients with 4 liver metastases, which
is traditionally regarded as the inclusion criteria for
metastasectomy.14
To date, numerous studies have reported a survival benefit
after liver metastasectomy. Most of the published data re-
ported the OS and PFS rates after metastasectomy. The OS
rate after liver metastasectomy was significantly different
between initial stage I/II and III/IV disease (Fig. 3B).
However, in the literature, almost all data was analyzed under
the hypothesis that all patients receiving the liver meta-
stasectomy were in the same group. Indeed, we found that they
differed according to OS. This difference partially contributes
to the wide range of OS after liver metastasectomy reported in
the literature. Only a few reviews have indicated the impor-
tance of initial disease stage.15e19 Furthermore, an important
issue concerns which factors contributed to significantly better
PFS and OS rates after metastasectomy in patients with initial
stage I/II disease. We believe this can be partially explained by
a lower recurrence rate in initial stage I/II patients, despite the
fact that most of them relapsed within 3 years as stage III/IV
disease (Fig. 4).Many clinical features have been suggested as prognostic
factors.20,21 However, results vary considerably from study to
study. In our study, parameters including age, sex, primary
disease stage, location, metastatic tumor distribution, number
of metastasis, CEA, adjuvant chemotherapy and synchronicity
were examined (Tables 3 and 4). Adjuvant chemotherapy after
liver metastasectomy (neither 5-fluorouracil nor oxaliplatin/
irinotecan based) showed no significant survival benefit in our
cohort, which was similar to other pooled analyses.22 The
primary tumor stage, the number of metastases in the liver at
the time of liver metastasectomy, and the metastatic tumor
distribution affected the OS significantly on univariate anal-
ysis, but only the initial disease stage was a significant prog-
nostic factor after multivariate analysis. Based on our analysis,
we believe that patients who receive liver metastasectomy
should be divided into those with initial stage IeII disease and
those with stage IIIeIV disease for analysis.
A total of 74/131 (56%) patients who underwent liver
metastasectomy developed recurrence, which is similar to
previous reports; this indicated a recurrence rate of 40% to
80%.23,24 Although few relapses occurred in stage I/II patients,
most of the relapse events occurred within 30 months, and
none occurred beyond 5 years from the time of diagnosis.
Thus, the relapse distribution is similar. In addition, the 5-year
progression free interval after liver metastasectomy could be
the boundary that distinguishes a cure from a fatal outcome.
Our study was limited in that most of the patients (96.2%)
had 4 liver metastases at the time of metastasectomy.
Table 4
Multivariate analysis of possible prognostic factors on overall survival after
liver metastasectomy.
Hazard ratio (95% CI) p value
Primary tumor stage
Stage I/II 1 0.020
Stage III/IV 5.357 (1.299-22.097)
Metastatic tumor distribution
Unilobar 1 0.158
More than unilobar 1.496 (0.856-2.614)
Number of metastases
<4 1 0.084
4 1.308 (0.964-1.774)
CI¼ confidence interval.
Table 3
Factors associated with overall survival after liver metastasectomy in univar-
iate analysis.
Number of patients 5-y survival (%) p value
Overall survival 131 42.1
Sex
Male 82 41.1 0.351
Female 49 43.6
Age
60 59 37.7 0.455
>61 72 45.1
Location
Right 57 36.7 0.139
Left 74 46.4
Diagnosis interval
Synchronous 77 37.2 0.419
Metachronous 54 50.5
Primary tumor stage
Stage I/II 15 83.9 0.006
Stage III/IV 116 35.7
Number of metastases
<4 122 43.3 0.003
4 9 25.0
Metastatic tumor distribution
Unilobar 83 52.9 0.038
More than unilobar 48 27.7
CEA ng/mL
20 86 48.1 0.083
>20 45 25.4 0.780
Adjuvant chemotherapy
Yes 113 40.1
No 18 52.6
CEA: carcinoembryonic antigen.
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sive liver metastasectomies.
In conclusion, our results suggest that patients who receive
liver metastasectomy for metastatic colon cancer should be
grouped into two groups, those with initial stages I and II
disease, and those with stages III and IV disease, since the PFS
and OS after liver metastasectomy in these two groups differ
significantly.References
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